Down-regulation of microRNA-142-3p inhibits the aggressive phenotypes of rheumatoid arthritis ﬁbroblast-like synoviocytes through inhibiting nuclear factor- κ B signaling

The present study aimed to investigate the regulatory roles of miR-142-3p on the aggressive phenotypes of rheumatoid arthritis (RA) human fibroblast-like synoviocytes (RA-HFLSs), and reveal the potential mechanisms relating with nuclear factor- κ B (NF- κ B) signaling. miR-142-3p expression was detected in RA synovial tissues and RA-HFLSs by quantitative real-time PCR (qRT-PCR) and Northern blot analysis. RA-HFLSs were transfected with miR-142-3p inhibitor and/or treated with 10 μ g/l tumor necrosis factor α (TNF- α ). The viability, colony formation, apoptosis, migration, invasion, and the levels of interleukin (IL)-6, and matrix metalloproteinase 3 (MMP-3) were detected. The mRNA expressions of B-cell lymphoma-2 (Bcl-2), Bax, Bad, IL-6, and MMP-3 were detected by qRT-PCR. Moreover, the expression of Bcl-2, IL-1 receptor-associated kinase 1 (IRAK1), Toll-like receptor 4 (TLR4), NF- κ B p65, and phosphorylated NF- κ B p65 (p-NF- κ B p65) were detected by Western blot. The interaction between IRAK1 and miR-142-3p was identified by dual luciferase reporter gene assay. MiR-142-3p was up-regulated in RA synovial tissues and RA-HFLSs. TNF- α activated the aggressive phenotypes of RA-HFLSs, including enhanced proliferation, migration, invasion, and inflammation, and inhibited apoptosis. miR-142-3p inhibitor significantly decreased the cell viability, the number of cell clones, the migration rate, the number of invasive cells, the contents and expression of IL-6 and MMP-3, and increased the apoptosis rate and the expressions of Bax and Bad, and decreased Bcl-2 expression of TNF- α -treated RA-HFLSs. MiR-142-3p inhibitor significantly reversed TNF- α -induced up-regulation of IRAK1, TLR4, and p-NF- κ B p65 in TNF- α -treated RA-HFLSs. Besides, IRAK1 was a target of miR-142-3p. The down-regulation of miR-142-3p inhibited the aggressive phenotypes of RA-HFLSs through inhibiting NF- κ B signaling. p65 in TNF- α -treated RA-HFLSs. These results illustrate that the down-regulation of miR-142-3p inhibits TNF- α -induced activation of NF- κ B signaling in RA-HFLSs. We suspect that the down-regulation of miR-142-3p may relieve the aggressive phenotypes of RA-HFLSs through inhibiting NF- κ B signaling. Besides, our further assays showed that IRAK1 was a target of miR-142-3p. Since IRAK1 is partially responsible for IL1-induced activation of NF- κ B signaling [46], the down-regulation of miR-142-3p may inhibit NF- κ B signaling by targeting IRAK1. In conclusion, miR-142-3p was up-regulated in RA synovial tissues and RA-HFLSs. The down-regulation of miR-142-3p significantly relieved TNF- α -induced aggressive phenotypes of RA-HFLSs, including enhanced proliferation, migration, invasion, and inflammation, as well as inhibited apoptosis. In addition, the down-regulation of


Introduction
Rheumatoid arthritis (RA) is a common autoimmune disease that affects 0.5-1% of the population worldwide [1]. RA is characterized by chronic inflammation in synovial tissues, and accompanied with the symptoms of pain, swelling, and stiffness of the joints [2]. Since RA contributes the destruction of cartilage and bone, RA is considered as one of the most common causes of disability [3]. In clinic practice, the therapeutic strategies for RA mainly focus on the control of pain and inflammation, as well as the protection of joint damage [4]. With the increasing revelation of the molecular mechanisms involved in the pathogenesis of RA, molecular targeting therapy has become a promising therapeutic strategy for RA.
Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine that plays a key role in the pathogenesis of RA [5]. Since activated TNF-α is closely associated with the inflammation of synovial tissues, anti-TNF-α has become a promising therapeutic target for RA [6]. Until now, drugs targeting TNF-α have been widely applied in the treatment of RA, such as adalimumab, etanercept and infliximab [7,8]. However, the long-term application of TNF-α antagonists may be accompanied with the risk of infection and malignancy [9,10]. Therefore, novel therapeutic strategies for RA with high efficiency and safety are urgently needed.
In the present study, the expression of miR-142-3p was detected in both RA synovial tissues and RA-HFLSs. The regulatory effects of miR-142-3p on the aggressive phenotypes of RA-HFLSs, including the proliferation, apoptosis, migration, invasion, and inflammation were evaluated. In addition, the potential regulatory mechanisms of miR-142-3p related with nuclear factor-κB (NF-κB) signaling were further analyzed. Our findings may not only provide a novel therapeutic target for RA, but also reveal new insights into the underlying mechanisms of RA.

Methods Patients
A total of ten RA patients (six males and four females, 52 + − 4 years old) were screened from our hospital between February 2017 and October 2017. During the same period, ten OA patients (three males and seven females, 52 + − 5 years old) were randomly screened. Both OA and RA were diagnosed according to the criteria established by the American College of Rheumatology. The present study was approved by the local Institutional Review Board, and informed consents were obtained from all subjects.

Isolation and culturing of HFLSs
RA-HFLSs and OA-HFLSs were isolated from synovial tissues of RA and OA patients, respectively. Simply, synovial tissues were washed with phosphate buffer saline (PBS), cut into fragments, and digested with 0.1% Type-I collagenase (Sigma, St. Louis, MO, U.S.A.) for 4 h at 37 • C. Followed by 5 min of centrifugation at 1000 rpm/min, HFLSs were resuspended in High-glucose Dulbecco's modified eagle medium (H-DMEM) (Hyclone, Thermo Fisher Scientific, Waltham, MA, U.S.A.) containing 10% fetal bovine serum (FBS). Normal HFLSs, and HEK-293T cells (human renal epithelial cell line) were purchased from The Cell Bank of Chinese Academy of Sciences (Shanghai, China), and maintained in H-DMEM containing 10% FBS. All cells were cultured in a humidified incubator at 37 • C with 5% CO 2 . The medium was refreshed every 2 days, and cells were passaged until 80-90% confluence. Logarithmic growth phase cells (third to eigth generation) were used for treatments.

MTT assay
MTT was performed to detect the viability of RA-HFLSs. Simply, 200 μl RA-HFLSs were seeded in 96-well plates at a density of 6×10 3 cells/well, and then incubated with 20 μg MTT (Sigma) for 4 h. After removing the medium, 150 μl DMSO was added into each well. Optical density (OD) at 495 nm was detected by a Microplate Reader (Molecular Devices, Sunnyvale, CA, U.S.A.).

Colony formation assay
Colony formation assay was performed to detect the colony-forming ability of RA-HFLSs. Simply, RA-HFLSs were seeded in 6-well plates at a density of 500 cells/well, and cultured for 14 days. After removing the medium, the colonies were fixed in methanol for 15 min and stained with crystal violet for 15 min. The stained colonies were observed under microscope (Olympus, Tokyo, Japan), and counted by using the software of ImageJ version 1.48V (National Institutes of Health, Bethesda, MD, U.S.A.).

TUNEL assay
TUNEL assay was performed to detect the apoptosis of RA-HFLSs. Simply, RA-HFLSs were fixed in 4% paraformaldehyde for 1 h, permeabilized with 0.1% TritonX-100/0.1% sodium citrate for 2 min, and blocked with 3% H 2 O 2 for 10 min. Then cells were stained with TUNEL (Roche, Basel, Switzerland) in accordance with manufacturer's instructions. Positive-stained cells were observed under microscope (Olympus), and counted in five randomly selected fields (×100).

Wound healing assay
Wound healing assay was performed to detect the migratory ability of RA-HFLSs. Simply, RA-HFLSs were seeded in 6-well plates at a density of 5×10 5 cells/well. When reaching 90% confluence, a wound track was scored in each well with a pipette tip. The cell debris were removed by washing with PBS. After 48 h of culturing, the migrated cells were observed under microscope (Olympus), and the migratory distance was measured.

Transwell assay
Transwell assay was performed to detect the invasive ability of RA-HFLSs by using transwell chambers (BD, Franklin Lakes, NJ, U.S.A.). Simply, 100 μl cells were seeded in the upper chamber (pre-coated with Matrigel) at a density 1×10 5 cells/well. The lower chamber is filled with 500 μl DMEM containing 10% FBS. Followed by 48 h of incubation at 37 • C, cells on the upper chamber were removed with cotton swabs. Cells on the lower chamber were washed with PBS, fixed in 4% paraformaldehyde for 15 min, and stained with 0.1% crystal violet for 10 min. Positive-stained cells were observed under microscope (Olympus), and counted in five randomly selected fields (×100).

Enzyme-linked immunosorbent assay
The contents of IL-6, and matrix metalloproteinase 3 (MMP-3) were detected in RA-HFLSs by using enzyme-linked immunosorbent assay (ELISA) kits (eBioscience, Thermo Fisher Scientific) in accordance with manufacturer's instructions. The OD at 450/550 nm was measured by a Microplate Reader (Molecular Devices).

Statistical analyses
All data were expressed as mean + − standard deviation. Statistical analysis was performed by SPSS version 18.0 (SPSS Inc., Chicago, IL, U.S.A.). Comparison between different groups was determined by t test (two groups) or one-way ANOVA (more than two groups). A P value less than 0.05 represented significantly different.

MiR-142-3p was up-regulated in RA
The expression of miR-142-3p was detected in both RA tissues and RA-HFLSs. qRT-PCR showed that the expression of miR-142-3p in synovial tissues was significantly higher in RA patients than in OA patients, and was significantly higher in RA patients at stage IV than in those at stage III (P<0.05) ( Figure 1A,B). RA-and OA-HFLSs were isolated from synovial tissues of RA and OA patients, respectively. The expression of miR-142-3p was significantly higher in RA-HFLSs than in OA-HFLSs (P<0.05). No significant difference on the expression of miR-142-3p was observed between OA-HFLSs and HFLSs (normal control) ( Figure 1C). Additionally, Northern blot analysis showed that miR-142-3p was significantly up-regulated in RA patients compared with OA patients ( Figure 1D). Similarly, expression of miR-142-3p in RA-HFLSs was higher than that in OA-HFLSs and TFLSs ( Figure 1E).

Down-regulation of miR-142-3p inhibited TNF-α-induced proliferation of RA-HFLSs
The viability of RA-HFLSs was detected by MTT assay. As shown in Figure 2A, the viability (OD 495 value) of RA-HFLSs was significantly increased with increasing concentrations of TNF-α in a dose-dependent manner until a peak at 10 μg/l (P<0.05). The results of Figure 2B showed the mRNA expression of miR-142-3p in inhibitor

Down-regulation of miR-142-3p promoted TNF-α-induced apoptosis of RA-HFLSs
The apoptosis of RA-HFLSs was detected by TUNEL staining. As shown in Figure 3A,B, the apoptosis rate of RA-HFLSs was significantly lower in TNF-α group than in Mock group (P<0.05). The transfection of miR-142-3p inhibitor significantly increased the apoptosis rate of TNF-α-treated RA-HFLSs (P<0.05) ( Figure 3A

Down-regulation of miR-142-3p inhibited TNF-α-induced migration and invasion of RA-HFLSs
The migration and invasion of RA-HFLSs was detected by wound healing assay and transwell assay, respectively. As shown in Figure 4A, the migration rate of RA-HFLSs was significantly higher in TNF-α group than in Mock group (P<0.05). The transfection of miR-142-3p inhibitor significantly decreased the migration rate of TNF-α-treated RA-HFLSs (P<0.05). The migration of RA-HFLSs was not significantly influenced by the transfection of INC ( Figure  4A). Consistent results with the migration rate were observed on the number of invasive RA-HFLSs ( Figure 4B).

Down-regulation of miR-142-3p inhibited TNF-α-induced inflammation of RA-HFLSs
The inflammation of RA-HFLSs was evaluated by the levels of IL-6 and MMP-3. As shown in Figure 5A,B, the con-

Discussion
HFLSs are key effector cells in RA, which exhibit aggressive phenotypes, such as enhanced proliferation and migration, and the overproduction of inflammatory cytokines and chemokines [27,28]. TNF-α is a proinflammatory cytokine that plays a key regulatory role in the aggressive phenotypes of RA-HFLSs. It has been reported that TNF-α promotes the proliferation, migration, invasion, and MMPs expression in RA-HFLSs [29]. TNF-α induces the proliferation of RA-HFLSs, and the production of IL-6 and IL-1β [30]. In the present study, we found that TNF-α-treated RA-HFLSs exhibited significantly increased cell viability, number of cell clones, migration rate, number of invasive cells, expression of Bcl-2, and levels of IL-6 and MMP-3, as well as decreased apoptosis rate. Our findings are just consistent with pervious studies, and further illustrate that TNF-α activates the aggressive phenotypes of RA-HFLSs. MiR-142-3p is a specific miR that plays a dual role in tumorigenesis. miR-142-3p not only acts as a tumor suppressor in osteosarcoma [31], gastric cancer [32], colon cancer [33], and non-small-cell lung cancer [34], but also acts as a tumor promoter in pediatric brain tumor [35], renal cell carcinoma [36], and colorectal cancer [37]. Over the past decade, non-coding RNAs including miRNAs and lncRNA gradually become important regulators of inflammation [38]. Until now, the knowledge on roles of miR-142-3p on RA are still limited. In the present study, we found that the expression of miR-142-3p was significantly higher in synovial tissues and RA-HFLSs of RA patients than those of OA patients. These results are consistent with pervious studies on miR-146 [12], -155 [13], -203 [14], -221 [15], and -126 [16], and illustrate that miR-142-3p is up-regulated in RA. In addition, we also found that the expression of miR-142-3p in synovial tissues was significantly higher in RA patients at stage IV than in those at stage III. This result indicates that miR-142-3p expression may be positively associated with the severity of RA. A pervious study indicates that circulating peripheral blood miRs, including miR-16, -21, -24, -26a, -125a-5p, -125b, -126-3p, -223, and -451 are promising non-invasive biomarkers for the detection of RA [39]. We suspect that miR-142-3p may also be used as a biomarker for the diagnosis of RA.
The specific regulatory effects of miR-142-3p on the aggressive phenotypes of RA-HFLSs were further evaluated in the present study. We found that the transfection of miR-142-3p inhibitor significantly decreased the cell viability, the number of cell clones, the migration rate, the number of invasive cells, and the expression of Bcl-2 expression, and increased the expressions of Bax and Bad, and the apoptosis rate of TNF-α-treated RA-HFLSs. A pervious study has proved that the down-regulation of miR-221 inhibits the migration and invasion, and promotes the apoptosis of HFLSs [15]. Our findings are just consistent with miR-221, and illustrate that the down-regulation of miR-142-3p reverses the promoting effects of TNF-α on the proliferation, migration, and invasion of RA-HFLSs. In addition, evidences have proved that miR-142-3p is involved in the regulation of inflammatory process. For examples, miR-142-3p overexpression inhibits LPS-induced production of IL-1, IL-6, and TNF-α in articular cartilage tissues of OA mice [24]. MiR-142-3p overexpression alleviates bleomycin-induced production of IL-1 and TNF-α in MLE-12 cells [22]. In the present study, we found that the transfection of miR-142-3p inhibitor significantly decreased the contents and the expression of IL-6 and MMP-3 in TNF-α-treated RA-HFLSs. These results indicate that the down-regulation of miR-142-3p inhibits TNF-α-induced inflammation of RA-HFLSs. However, our findings are inconsistent with previous studies. Similar with the dual roles of miR-142-3p in tumorigenesis, we suspect that miR-142-3p may exert different regulatory roles on inflammation in different diseases. To sum up, the down-regulation of miR-142-3p may contribute to the amelioration of RA via relieving the aggressive phenotypes of RA-HFLSs, including the enhanced proliferation, migration, invasion, and inflammation, as well as inhibited apoptosis.
Since RA is a chronic inflammatory disease of the synovial joints, activated NF-κB is always detected in synovial tissues of RA [40]. In the present study, we found that TNF-α significantly up-regulated IRAK1, TLR4, and p-NF-κB p65 in RA-HFLSs. These results illustrate that TNF-α induces the activation of NF-κB signaling in RA-HFLSs. In RA-HFLSs, TNF-α stimulation can result in phosphorylation of NF-κB and activation of NF-κB, and then induce the expression of target genes involved in proinflammation, cell cycle, and anti-apoptosis [41]. TNF-α-induced activation of NF-κB signaling contributes to the aggressive phenotypes of RA-HFLSs. NF-κB is a common nuclear transcription factor appeared in osteoblasts. Studies have found that Runx [42], NF-κB signaling [43], and other pathways play important role in osteogenesis differentiation and activity. Cross talks between these pathways or together they regulate osteoblast activity. Disruption of Runx1 and Runx3 could result in bone marrow failure [44], and Runx3 deficiency leads to myeloproliferative disorder [45]. Changes in NF-κB pathway could regulate variations in osteogenesis activity. In the present study, the regulatory mechanisms of miR-142-3p relating with NF-κB signaling were further evaluated. We found that transfection of miR-142-3p inhibitor significantly down-regulated IRAK1, TLR4, and p-NF-κB p65 in TNF-α-treated RA-HFLSs. These results illustrate that the down-regulation of miR-142-3p inhibits TNF-α-induced activation of NF-κB signaling in RA-HFLSs. We suspect that the down-regulation of miR-142-3p may relieve the aggressive phenotypes of RA-HFLSs through inhibiting NF-κB signaling. Besides, our further assays showed that IRAK1 was a target of miR-142-3p. Since IRAK1 is partially responsible for IL1-induced activation of NF-κB signaling [46], the down-regulation of miR-142-3p may inhibit NF-κB signaling by targeting IRAK1.
In conclusion, miR-142-3p was up-regulated in RA synovial tissues and RA-HFLSs. The down-regulation of miR-142-3p significantly relieved TNF-α-induced aggressive phenotypes of RA-HFLSs, including enhanced proliferation, migration, invasion, and inflammation, as well as inhibited apoptosis. In addition, the down-regulation of miR-142-3p inhibited NF-κB signaling by targeting IRAK1, thereby contributing to the remission of TNF-α-induced aggressive phenotypes of RA-HFLSs. Down-regulation of miR-142-3p may be used as a promising therapeutic target for RA.